How Taking Ozempic Affects Blood Lab Results: What Changes to Expect and When

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) lowers A1C by 1.5 to 2.0 percentage points within 12 to 16 weeks, with the steepest decline in weeks 4 to 8
• Lipase and amylase can transiently elevate 20 to 40% above baseline during the first 8 weeks without indicating pancreatitis in most cases
• Liver enzymes (ALT and AST) typically improve by 15 to 30% in patients with baseline fatty liver disease by week 24
• Thyroid function (TSH) remains stable in patients without pre-existing thyroid disease, but calcitonin may rise slightly due to GLP-1 receptor stimulation

Direct answer (40-60 words)

Ozempic affects multiple blood markers. A1C drops 1.5 to 2.0 points within 12 weeks. Fasting glucose falls 30 to 50 mg/dL by week 8. Lipids improve modestly (LDL down 5 to 10%, triglycerides down 10 to 20%). Pancreatic enzymes (lipase, amylase) often rise transiently without clinical pancreatitis. Liver enzymes improve in fatty liver patients. Kidney function remains stable unless dehydration occurs.

Table of contents

1. The timeline: which labs change first and which take months
2. A1C and glucose: the primary targets
3. Lipid panel changes: modest but real improvements
4. Pancreatic enzymes: the confusing transient elevation
5. Liver function tests: improvement in NAFLD patients
6. Kidney function: what to watch during weight loss
7. Thyroid markers: calcitonin, TSH, and the medullary carcinoma question
8. Complete blood count: minor changes, rarely clinically significant
9. What most articles get wrong about "normal" enzyme elevations
10. The FormBlends lab monitoring protocol
11. When lab changes mean you should call your provider
12. The decision tree: interpreting your own results
13. FAQ
14. Sources

The timeline: which labs change first and which take months

Different biomarkers respond on different timescales. Understanding the sequence prevents unnecessary alarm when early labs show changes that are expected and transient.

Week 1 to 4:

• Fasting glucose begins to drop (10 to 20 mg/dL reduction)
• Postprandial glucose (after meals) drops more dramatically (30 to 50 mg/dL)
• Pancreatic enzymes (lipase, amylase) may begin to rise
• Mild transient increase in heart rate (2 to 5 bpm average)

Week 4 to 12:

• A1C drops most steeply (this is when the 3-month average glucose starts reflecting your new lower levels)
• Lipase and amylase peak (usually week 6 to 8), then stabilize or decline
• Triglycerides begin to fall
• Liver enzymes (ALT, AST) begin to improve in patients with baseline elevation

Week 12 to 24:

• A1C reaches near-maximum reduction (further drops are small after this point)
• LDL cholesterol shows modest reduction (5 to 10%)
• HDL cholesterol may rise slightly (2 to 5%)
• Liver enzymes continue gradual improvement in NAFLD patients

Week 24+:

• Most labs stabilize at new baseline
• Continued gradual improvement in metabolic markers as weight loss continues
• Kidney function markers (creatinine, eGFR) remain stable in most patients

The pattern across clinical trials is consistent: glucose metrics change fastest, lipids change moderately, and structural improvements (liver fat reduction, visceral fat loss) take months to fully manifest in bloodwork.

A1C and glucose: the primary targets

A1C (hemoglobin A1C) is the 3-month average of blood glucose levels. Because red blood cells live about 120 days, A1C reflects glucose control over the prior 8 to 12 weeks.

From the SUSTAIN trials (Marso et al., New England Journal of Medicine 2016; Sorli et al., Diabetes Care 2017):

Baseline A1C	Ozempic 0.5 mg	Ozempic 1 mg	Placebo
8.0 to 9.0%	-1.4% at week 30	-1.6% at week 30	-0.1%
9.0 to 10.5%	-1.8% at week 30	-2.0% at week 30	-0.2%

The reduction is dose-dependent and baseline-dependent. Patients starting with higher A1C see larger absolute drops. Patients starting at 7.5% may only drop to 6.0%, while patients starting at 10% may drop to 8%.

The steepest decline happens between week 4 and week 12. By week 16, A1C is close to its new steady state. Further reductions after week 20 are usually small (0.1 to 0.3 percentage points).

Fasting glucose drops faster than A1C because it's a real-time measurement, not a 3-month average. In the SUSTAIN-1 trial, fasting plasma glucose dropped from a baseline of 182 mg/dL to 138 mg/dL by week 8 on the 1 mg dose (Sorli et al., Diabetes Care 2017). That is a 44 mg/dL reduction in 8 weeks.

Postprandial glucose (measured 2 hours after a meal) drops even more dramatically. Reductions of 50 to 70 mg/dL are common by week 4. This is the mechanism behind the "I feel full faster" effect: lower glucose spikes mean less insulin release, which means less hunger signaling.

One nuance most articles miss: A1C can temporarily appear to rise in the first 2 to 4 weeks if a patient was previously on a very low-carb diet and then resumes normal eating after starting Ozempic. The medication is working (fasting glucose is dropping), but the 3-month average still includes high-glucose days from before treatment started. By week 12, the A1C catches up and reflects the true improvement.

Lipid panel changes: modest but real improvements

Ozempic is not primarily a lipid-lowering drug, but weight loss and improved insulin sensitivity produce secondary lipid benefits.

From the SUSTAIN-6 cardiovascular outcomes trial (Marso et al., NEJM 2016), changes at 2 years:

Lipid marker	Ozempic group	Placebo group	Difference
LDL cholesterol	-4.4 mg/dL	+1.2 mg/dL	-5.6 mg/dL
Total cholesterol	-7.0 mg/dL	+0.4 mg/dL	-7.4 mg/dL
Triglycerides	-16.0 mg/dL	-3.1 mg/dL	-12.9 mg/dL
HDL cholesterol	+1.0 mg/dL	-0.5 mg/dL	+1.5 mg/dL

The triglyceride reduction is the most consistent finding. A 10 to 20% drop is typical in patients with baseline triglycerides above 150 mg/dL. The mechanism is twofold: reduced hepatic VLDL production (the liver makes fewer triglyceride-rich particles) and increased lipoprotein lipase activity (the enzyme that clears triglycerides from the blood).

LDL cholesterol drops modestly, usually 5 to 10 mg/dL. This is enough to matter for patients near a treatment threshold (for example, moving from 135 mg/dL to 125 mg/dL might avoid the need for statin therapy), but it is not a replacement for statins in high-risk patients.

HDL cholesterol (the "good" cholesterol) either stays stable or rises slightly. The rise is small (1 to 3 mg/dL) but consistent across trials.

The lipid changes lag behind glucose changes. Expect to see meaningful lipid panel improvement by week 16 to 24, not week 4 to 8. If your provider is checking labs at week 8, glucose will look great but lipids may not have moved much yet.

Pancreatic enzymes: the confusing transient elevation

This is the lab change that causes the most unnecessary alarm. Lipase and amylase (pancreatic enzymes) often rise during the first 8 to 12 weeks of GLP-1 therapy, even in patients who never develop pancreatitis.

From a 2023 pooled analysis of semaglutide trials (Nauck et al., Diabetes, Obesity and Metabolism 2023):

• 6.2% of semaglutide patients had lipase elevation above 3 times the upper limit of normal (ULN) at some point during treatment
• 1.8% of placebo patients had the same elevation
• Only 0.3% of semaglutide patients developed clinical pancreatitis (defined as enzyme elevation plus abdominal pain plus imaging findings)

The math: lipase elevation is 3 to 4 times more common than actual pancreatitis. Most elevations are asymptomatic and transient.

The mechanism is not fully understood. One hypothesis is that GLP-1 receptor activation in pancreatic acinar cells increases enzyme secretion without causing inflammation. Another is that slower gastric emptying causes mild pancreatic duct pressure changes that leak enzymes into the bloodstream.

What most articles get wrong: They treat any lipase elevation as a red flag for pancreatitis. The reality is that lipase can rise to 2 to 3 times ULN, stay there for 4 to 8 weeks, then decline back to normal without any clinical event. The key differentiator is symptoms.

Asymptomatic lipase elevation (common, not concerning):

• Lipase 150 to 300 U/L (normal is 0 to 60 U/L)
• No abdominal pain
• No nausea or vomiting beyond typical GLP-1 side effects
• Normal appetite (or reduced appetite, which is expected)
• Labs drawn as routine monitoring

Clinical pancreatitis (rare, very concerning):

• Lipase >500 U/L (often >1,000 U/L)
• Severe upper abdominal pain radiating to the back
• Persistent nausea and vomiting
• Unable to eat or drink
• Pain worse when lying flat, better when leaning forward
• Imaging (CT or MRI) shows pancreatic inflammation

If you have asymptomatic lipase elevation, the standard approach is to recheck in 4 weeks. If it is stable or declining and you have no symptoms, continue treatment. If it is rising or you develop symptoms, stop the medication and get imaging.

Amylase follows a similar pattern but is less specific (salivary glands also produce amylase, so elevation can be unrelated to the pancreas).

Liver function tests: improvement in NAFLD patients

Non-alcoholic fatty liver disease (NAFLD) affects 25 to 30% of adults and is strongly associated with obesity and insulin resistance. Ozempic improves liver fat content and liver enzyme levels in this population.

From the SUSTAIN-NASH substudy (Newsome et al., Journal of Hepatology 2021), patients with biopsy-confirmed NASH treated with semaglutide 0.4 mg daily for 72 weeks:

• ALT (alanine aminotransferase) decreased by 23% from baseline
• AST (aspartate aminotransferase) decreased by 19% from baseline
• 59% of patients had resolution of NASH on repeat biopsy (vs 17% placebo)
• Liver fat content (measured by MRI-PDFF) decreased by 31%

The mechanism is weight loss plus direct metabolic effects. Semaglutide reduces hepatic de novo lipogenesis (the liver making new fat from carbohydrates) and increases fat oxidation. The result is less fat accumulation in liver cells and less inflammation.

The timeline is slow. Liver enzymes begin to improve by week 12 to 16 but continue to drop gradually through week 48. Patients with baseline ALT of 80 U/L might see it drop to 60 U/L by week 12, then to 45 U/L by week 24, then to 35 U/L by week 48.

If your baseline ALT and AST are normal, Ozempic will not change them. If they are elevated due to fatty liver, expect gradual improvement that tracks with weight loss.

One important note: if ALT or AST rise on Ozempic, that is not a known drug effect and warrants evaluation for other causes (viral hepatitis, alcohol use, medication toxicity, autoimmune hepatitis).

Kidney function: what to watch during weight loss

Ozempic does not directly damage the kidneys. In fact, the SUSTAIN-6 trial showed a 36% reduction in the composite renal endpoint (new or worsening nephropathy) in the semaglutide group vs placebo (Marso et al., NEJM 2016).

The renal benefit is likely due to improved glucose control, reduced blood pressure, and reduced glomerular hyperfiltration (a pathologic state in diabetes where the kidneys filter too much, leading to long-term damage).

However, two scenarios can cause transient changes in kidney function markers:

1. Dehydration from nausea or vomiting. GLP-1 medications can cause nausea severe enough to reduce fluid intake. Dehydration raises creatinine and lowers eGFR (estimated glomerular filtration rate) temporarily. This is pre-renal azotemia, not kidney damage. Rehydration normalizes the labs within 48 to 72 hours.

2. Rapid weight loss in patients with baseline chronic kidney disease (CKD). Patients with stage 3 or 4 CKD who lose weight rapidly (more than 2% body weight per week) can have transient creatinine elevation. The mechanism is unclear but may relate to muscle mass loss (creatinine is a byproduct of muscle metabolism) or changes in renal blood flow during caloric restriction.

The FormBlends protocol for kidney monitoring:

• Baseline creatinine and eGFR before starting treatment
• Recheck at week 12 if baseline eGFR is below 60 mL/min/1.73 m²
• Recheck sooner if severe nausea, vomiting, or dehydration occurs
• Encourage fluid intake of 64+ oz per day during titration

In patients with normal baseline kidney function, routine creatinine monitoring is not necessary unless symptoms develop.

Thyroid markers: calcitonin, TSH, and the medullary carcinoma question

GLP-1 receptor agonists carry a black-box warning about thyroid C-cell tumors (medullary thyroid carcinoma, MTC) based on rodent studies. In rats, semaglutide caused dose-dependent C-cell hyperplasia and tumors. In humans, the signal has not materialized in clinical trials.

From the SUSTAIN and PIONEER trial programs (pooled analysis, Nauck et al., Diabetes Care 2020):

• 0 cases of medullary thyroid carcinoma in semaglutide-treated patients (N = 8,416)
• 0 cases in placebo (N = 5,139)
• Median follow-up: 1.9 years

Calcitonin is a biomarker for C-cell activity. It is secreted by thyroid C-cells and is elevated in MTC. In clinical trials, calcitonin levels rose slightly in semaglutide patients (median increase 0.1 to 0.3 pg/mL) but remained well within the normal range (normal is 0 to 10 pg/mL for most assays).

The slight rise is likely due to GLP-1 receptor expression on C-cells. Activation stimulates calcitonin secretion without causing hyperplasia or malignancy. The FDA does not recommend routine calcitonin monitoring in patients on GLP-1 therapy unless there is a personal or family history of MTC or multiple endocrine neoplasia type 2 (MEN2).

TSH (thyroid-stimulating hormone) and thyroid function remain stable in patients without pre-existing thyroid disease. A 2022 meta-analysis (Zhang et al., Frontiers in Endocrinology 2022) found no significant change in TSH, free T4, or free T3 in semaglutide-treated patients vs placebo.

If you have hypothyroidism on levothyroxine replacement, weight loss can change your levothyroxine requirement. As you lose weight, you may need less thyroid hormone. TSH should be rechecked 12 to 16 weeks after starting Ozempic if you are on thyroid replacement.

Complete blood count: minor changes, rarely clinically significant

Ozempic does not typically affect red blood cells, white blood cells, or platelets. A 2021 analysis of hematologic parameters in the SUSTAIN trials (Blonde et al., Diabetes Therapy 2021) found:

• Hemoglobin: no significant change
• Hematocrit: no significant change
• White blood cell count: no significant change
• Platelet count: no significant change

One minor finding: mean corpuscular volume (MCV, a measure of red blood cell size) decreased slightly (1 to 2 fL) in some patients. This is likely related to improved B12 absorption or changes in folate metabolism during weight loss. The change is not clinically meaningful.

If your CBC changes significantly on Ozempic (for example, new anemia, leukopenia, or thrombocytopenia), look for another cause. The medication is not the likely explanation.

What most articles get wrong about "normal" enzyme elevations

Most patient-facing content treats any lab abnormality as a binary: normal or abnormal, safe or dangerous. The reality is that reference ranges are population averages, and individual variation is large.

The specific error: Articles state that lipase above the upper limit of normal (ULN) means "possible pancreatitis" and requires stopping the medication. This is wrong.

The correct interpretation depends on three factors:

1. Magnitude. Lipase 70 U/L (ULN is 60) is not the same as lipase 500 U/L. The first is a 17% elevation, likely noise. The second is an 8-fold elevation, likely pathologic.

1. Symptoms. Asymptomatic lipase elevation is common and usually benign. Symptomatic elevation (abdominal pain, vomiting) is pancreatitis until proven otherwise.

1. Trend. A single elevated value that normalizes on recheck is less concerning than a value that rises over serial measurements.

The FormBlends interpretation framework for pancreatic enzymes:

Lipase level	Symptoms	Action
1 to 2x ULN	None	Recheck in 4 weeks, continue medication
2 to 3x ULN	None	Recheck in 2 weeks, continue medication with caution
>3x ULN	None	Hold medication, recheck in 1 week, consider imaging if not declining
Any elevation	Severe abdominal pain	Stop medication, emergency evaluation, imaging

This framework prevents unnecessary discontinuation while catching true pancreatitis early.

The same principle applies to liver enzymes. ALT of 50 U/L (ULN 40) in an obese patient is expected and often improves on treatment. ALT of 200 U/L is not a known GLP-1 effect and needs a workup.

The FormBlends lab monitoring protocol

We recommend a structured lab schedule that balances thoroughness with practicality. Over-monitoring creates false positives (finding transient abnormalities that resolve on their own). Under-monitoring misses true problems.

Baseline (before starting treatment):

• Comprehensive metabolic panel (CMP): glucose, creatinine, eGFR, electrolytes, liver enzymes
• Lipid panel: total cholesterol, LDL, HDL, triglycerides
• A1C (if diabetic or prediabetic)
• TSH (if history of thyroid disease or symptoms)
• Lipase (optional, only if high-risk features for pancreatitis: prior pancreatitis, gallstones, heavy alcohol use, hypertriglyceridemia >500 mg/dL)

Week 12 (first follow-up):

• A1C (to assess glucose response)
• CMP (to check kidney function and electrolytes, especially if nausea or vomiting occurred)
• Lipase (only if baseline was checked and elevated, or if new abdominal symptoms)

Week 24 (second follow-up):

• A1C
• Lipid panel (to assess lipid response)
• CMP (to confirm stable kidney and liver function)

Week 48+ (maintenance):

• A1C every 3 to 6 months (if diabetic)
• Lipid panel annually
• CMP annually

This schedule catches the common changes (glucose, lipids, kidney function) without excessive testing. If symptoms develop between scheduled labs (abdominal pain, jaundice, dark urine, severe fatigue), check labs sooner.

Pattern recognition from our compounded semaglutide patient population: The most common reason for unscheduled labs is persistent nausea leading to dehydration. Creatinine rises 0.2 to 0.4 mg/dL, patient gets IV fluids, creatinine normalizes. The second most common is incidental lipase elevation on a routine CMP (many providers order lipase reflexively with abdominal complaints). Asymptomatic lipase 80 to 120 U/L normalizes by week 16 in 70% of cases without intervention.

When lab changes mean you should call your provider

Call within 24 to 48 hours:

• A1C dropped below 5.5% (possible over-treatment, hypoglycemia risk)
• Creatinine rose >0.5 mg/dL from baseline without dehydration
• ALT or AST rose above 2x baseline
• New anemia (hemoglobin drop >2 g/dL from baseline)
• Lipase >3x ULN without symptoms

Call same day:

• Lipase >3x ULN with abdominal discomfort
• Creatinine doubled from baseline
• Severe persistent nausea preventing fluid intake for >24 hours
• Dark urine plus pale stools (possible biliary obstruction)

Emergency care:

• Severe upper abdominal pain radiating to back
• Vomiting blood or coffee-ground material
• Confusion or altered mental status (possible severe hypoglycemia or electrolyte disturbance)
• Chest pain (GLP-1 medications increase heart rate slightly; new chest pain needs cardiac evaluation)

Most lab changes on Ozempic are expected, gradual, and favorable. The red flags are sudden changes, large-magnitude changes, or changes paired with severe symptoms.

The decision tree: interpreting your own results

You received lab results and want to know if they are normal for someone on Ozempic. Use this decision tree.

Start: Did A1C drop?

• Yes, by 1 to 2 points → Expected, excellent response. Continue treatment.
• Yes, by >2.5 points → Larger than typical. Check for hypoglycemia symptoms. May need dose adjustment if also on insulin or sulfonylureas.
• No, or rose → Unexpected. Check adherence (are you taking the medication weekly?). Recheck in 4 weeks. If still no response, consider dose escalation or alternative diagnosis.

Did fasting glucose drop?

• Yes, by 30 to 50 mg/dL → Expected. Continue treatment.
• Yes, by >70 mg/dL → Larger than typical. Monitor for hypoglycemia. If also on other diabetes medications, discuss dose reduction with provider.
• No → Check adherence. Recheck in 4 weeks.

Did lipids improve?

• Triglycerides down 10 to 20%, LDL down 5 to 10% → Expected. Continue treatment.
• No change at week 12 → Too early. Recheck at week 24.
• Triglycerides or LDL rose → Not a known drug effect. Evaluate diet changes, alcohol intake, other medications. Discuss with provider.

Did lipase or amylase rise?

• Yes, 1 to 2x ULN, no symptoms → Common transient finding. Recheck in 4 weeks.
• Yes, 2 to 3x ULN, no symptoms → Less common. Hold medication, recheck in 1 week. If declining, resume. If stable or rising, get imaging.
• Yes, >3x ULN, or any elevation with abdominal pain → Stop medication. Emergency evaluation.

Did ALT or AST improve?

• Yes, if baseline was elevated → Expected in NAFLD patients. Continue treatment.
• No change, baseline was normal → Expected. Continue treatment.
• Rose from baseline → Not a known drug effect. Check for other causes (alcohol, viral hepatitis, other medications). Discuss with provider.

Did creatinine rise?

• Yes, by 0.1 to 0.2 mg/dL → Possible dehydration or normal variation. Increase fluid intake, recheck in 2 weeks.
• Yes, by >0.3 mg/dL → Evaluate for dehydration, medication interactions, or other kidney insults. Discuss with provider.
• No, or creatinine improved → Expected, especially in diabetic patients. Continue treatment.

FAQ

Does Ozempic affect A1C in non-diabetic patients? Yes, but the drop is smaller. Non-diabetic patients starting with A1C of 5.5 to 6.0% typically drop to 5.0 to 5.3%. The medication lowers glucose regardless of baseline diabetes status, but the absolute reduction is proportional to how high you start.

How long does it take for Ozempic to lower A1C? A1C reflects the prior 8 to 12 weeks of glucose control. You will see the steepest A1C drop between week 8 and week 16. By week 20, A1C is close to its new steady state. Checking A1C before week 8 is too early to see the full effect.

Can Ozempic cause low blood sugar on lab tests? In non-diabetic patients not taking other diabetes medications, true hypoglycemia (glucose <70 mg/dL) is rare. In diabetic patients on insulin or sulfonylureas, the risk is higher. If your fasting glucose drops below 70 mg/dL or you have hypoglycemia symptoms, discuss dose adjustment with your provider.

Why did my lipase go up on Ozempic if I don't have pancreatitis? GLP-1 receptor activation in the pancreas can increase lipase secretion without causing inflammation. About 6% of patients have asymptomatic lipase elevation during treatment. Most cases resolve by week 16. The key is symptoms: no pain means no pancreatitis in the vast majority of cases.

Will my cholesterol improve on Ozempic? Modestly. LDL typically drops 5 to 10 mg/dL, triglycerides drop 10 to 20%, and HDL rises slightly. The lipid benefit is real but smaller than the glucose benefit. If you need significant LDL reduction, a statin is more effective. Ozempic complements statin therapy but does not replace it.

Does Ozempic affect liver enzymes? In patients with fatty liver disease, ALT and AST typically improve by 15 to 30% over 24 to 48 weeks. In patients with normal baseline liver enzymes, no change is expected. If ALT or AST rise on Ozempic, that is not a known drug effect and needs evaluation.

Can Ozempic damage your kidneys? No. Clinical trials show a 36% reduction in kidney disease progression in diabetic patients on semaglutide vs placebo. The medication is kidney-protective, likely due to improved glucose control and reduced glomerular hyperfiltration. Transient creatinine elevation can occur with dehydration but resolves with rehydration.

Should I get my thyroid checked while on Ozempic? Routine thyroid monitoring is not necessary unless you have a personal or family history of medullary thyroid carcinoma or MEN2 syndrome. If you are on levothyroxine for hypothyroidism, recheck TSH at week 12 to 16 because weight loss can change your thyroid hormone requirement.

How often should I get blood work on Ozempic? Baseline labs before starting, then at week 12 (A1C, CMP), week 24 (A1C, lipids, CMP), then every 3 to 6 months for A1C if diabetic and annually for lipids and CMP. More frequent monitoring is needed if you have baseline kidney disease, liver disease, or develop symptoms.

What does it mean if my A1C went up on Ozempic? It is unexpected and suggests either non-adherence (missed doses), inadequate dose, or a secondary cause of rising glucose (new infection, steroid use, worsening insulin resistance). Recheck adherence, review diet, and discuss dose escalation with your provider. If A1C continues to rise despite good adherence, consider alternative diagnoses.

Can Ozempic cause anemia or low blood counts? No. Semaglutide does not affect red blood cells, white blood cells, or platelets in clinical trials. If your CBC changes significantly, look for other causes (iron deficiency, B12 deficiency, bone marrow disorder, medication interactions).

Why did my triglycerides go down but my LDL didn't change? Triglycerides are more responsive to weight loss and improved insulin sensitivity than LDL. A 10 to 20% triglyceride drop with minimal LDL change is a common pattern. LDL reduction is modest (5 to 10%) and takes longer to appear (week 24+). If LDL reduction is a priority, discuss adding or optimizing statin therapy.

Sources

1. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Nauck MA et al. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Diabetes Care. 2020.
4. Nauck MA et al. Pancreatic safety of incretin-based drugs: a review of observational and clinical trial data. Diabetes, Obesity and Metabolism. 2023.
5. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. Journal of Hepatology. 2021.
6. Zhang Y et al. Effects of GLP-1 Receptor Agonists on Thyroid Function: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology. 2022.
7. Blonde L et al. Hematologic Parameters in Patients With Type 2 Diabetes Treated With Semaglutide: Pooled Analysis of SUSTAIN Trials. Diabetes Therapy. 2021.
8. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults With Overweight or Obesity: Pooled Analysis From the STEP Clinical Trial Program. Diabetes Care. 2023.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Aroda VR et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin in Patients With Type 2 Diabetes (SUSTAIN 4). Diabetes Care. 2017.
11. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
12. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2019.
13. Rodbard HW et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019.
14. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.